Tryp Therapeutics is a pharmaceutical company focused on identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs.
The company has two active development programs: one exploring psilocybin for neuropsychiatric disorders, and the other is developing Razoxane for soft tissue sarcoma.
Under its Psilocybin-for-Neuropsychiatric Disorders (PFN™ ) Program, the Company is developing psilocybin-based therapeutics for neuropsychiatric indications, and plans to seek regulatory approval in-line with the FDA regulatory pathway.
Tryp intends to leverage existing third-party preclinical and clinical data to expedite their drug development programs. This is allowed for under the FDA’s Section 505(b)(2) pathway, which permits the submission of New Drug Applications (NDAs) that rely in part on third-party investigations.